Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
DOI: 10.1002/cpdd.34
Authors: Rebecca J. Hodge, Jiang Lin, Lakshmi S. Vasist Johnson, Elizabeth P. Gould, Gary D. Bowers, Derek J. Nunez, on behalf of the SB‐756050 Project Team
Institution: GlaxoSmithKline (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: NIH Clinical Center
OpenAlex ID: W1541434960
